Stockscreener 앱 받기
10.21
0.20%
-0.02
시간 외 거래:
10.21
전일 마감가:
$10.23
열려 있는:
$10.21
하루 거래량:
20,799
Relative Volume:
1.90
시가총액:
$219.49M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+0.00%
1개월 성능:
+0.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$10.21
$10.25
1주일 범위
$10.20
$10.35
52주 변동 폭
$10.20
$10.35
Helix Acquisition Corp Iii Stock (HLXC) Company Profile
HLXC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HLXC
Helix Acquisition Corp Iii
|
10.21 | 219.92M | 0 | 0 | 0 | 0.00 |
|
LION
Lionsgate Studios Corp
|
9.44 | 2.75B | 3.13B | -174.20M | -111.20M | -0.6937 |
|
XXI
Twenty One Capital Inc
|
7.60 | 2.63B | 0 | 0 | 0 | 0.00 |
|
CCCX
Churchill Capital Corp X
|
13.50 | 804.69M | 0 | 0 | 0 | 0.00 |
|
DMII
Drugs Made In America Acquisition Ii Corp
|
9.97 | 653.13M | 0 | 0 | 0 | 0.00 |
|
CEPF
Cantor Equity Partners Iv Inc
|
10.47 | 597.79M | 0 | 0 | 0 | 0.00 |
Helix Acquisition Corp Iii 주식(HLXC)의 최신 뉴스
Helix Acquisition Corp. III completes $172.5 million IPO and private placement - Investing.com
Helix Acquisition Corp. III Completes Initial Public Offering - TradingView
Finance Watch: SPACs Attempt A Comeback As IPO Market Shows Signs Of Life - Citeline News & Insights
With a Thin IPO Calendar, Hedge Funds Are Zeroing In on Biopharma - Institutional Investor
Helix Acquisition prices $150M initial public offering - MSN
Will Helix Acquisition Corp. II stock continue dividend increasesRate Cut & AI Forecast Swing Trade Picks - mfd.ru
Helix Acquisition Corp. III raises $172.5 million in Nasdaq IPO By Investing.com - Investing.com Nigeria
Helix Acquisition Corp III closes $172.5 million IPO By Investing.com - Investing.com South Africa
Helix Acquisition Corp. III closes $172.5 million IPO By Investing.com - Investing.com Australia
Helix Acquisition Corp. III raises $172.5 million in Nasdaq IPO - Investing.com
Helix Acquisition Corp. III closes $172.5 million IPO - Investing.com India
Helix Acquisition Corp. III Announces Closing of $172.5 Million Initial Public Offering, Including the Full Exercise of the Underwriter's Option to Purchase Additional Shares - The Manila Times
SL Green Realty Corp. Announces Date of 2026 Annual Meeting of Stockholders - The Manila Times
White & Case advises Helix Acquisition Corp. III on upsized US$150 million IPO - White & Case LLP
Biotech investor Cormorant secures $150M for another SPAC deal - BioPharma Dive
Helix Acquisition III Raises $150 Million, Targets Healthcare Sector - Intellectia AI
Helix Acquisition Corp. III Prices Upsized $150 Mln IPO - Nasdaq
Helix Acquisition Corp. III Announces Pricing of Upsized $150 Million Initial Public Offering - The Manila Times
Helix Acquisition III launches $150M healthcare-focused SPAC IPO - Stock Titan
Day One was one of three parties interested in Mersana; Bihua Chen and Cormorant’s third SPAC - Endpoints News
HLXC IPO NewsCormorant's SPAC Helix Acquisition III files for a $125 million IPO, targeting healthcare - renaissancecapital.com
BBOT Debuts as a Publicly Traded Company Focused on - GlobeNewswire
BridgeBio Oncology Lands Massive $382M SPAC Deal as Top Investors Back Cancer Drug Pipeline - Stock Titan
BridgeBio Oncology's SPAC Merger Advances: SEC Clears Path for Novel Cancer Drug Development Platform - Stock Titan
Longevity Biotech Takes Root on Nasdaq With $180M SPAC Deal - BioSpace
Helix Acquisition Corp. II SEC 10-Q Report - TradingView
Swiss ADC Biotech Takes SPAC Track to NASDAQ - BioSpace
BridgeBio Oncology and Helix enter definitive merger agreement - Pharmaceutical Technology
BridgeBio spinout to go public in SPAC deal (HLXB:NASDAQ) - Seeking Alpha
Life Sciences Hedge Fund Perceptive Preps a New SPAC - Institutional Investor
Helix Acquisition Corp. II Closes of $184 Million IPO - citybiz
Helix Acquisition Corp. II Prices of Upsized $160 Million IPO - citybiz
Cormorant Launches Second SPAC Following MoonLake Deal with $100M IPO - BioSpace
MoonLake Immunotherapeutics AG and Helix Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing Tri-specific Nanobody® Sonelokimab - Business Wire
Helix Acquisition Corp Iii (HLXC) 재무 분석
Helix Acquisition Corp Iii (HLXC)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.64%
0.00%
자본화:
|
볼륨(24시간):